Rumor: AstraZeneca PLC Actively Pursued Forest Laboratories, Inc.
Published: Feb 26, 2014
British drug maker AstraZeneca AZN.LN -0.43% PLC recently made an abortive acquisition approach to Forest Laboratories Inc. FRX +1.16% before the specialty-drug company agreed last week to be bought by Actavis PLC for $25 billion, according to people familiar with the matter. Late last year, AstraZeneca approached Forest about a deal for around $70 a share, according to some of the people. The cash-and-stock deal that Actavis ACT +2.16% sealed valued Forest at $89.48 a share.
Help employers find you! Check out all the jobs and post your resume.